We hypothesized that platelet-activating factor (PAF), a potent inflammatory mediator, could induce gas exchange abnormalities in normal humans. To this end, the effect of aerosolized PAF (2 mg/ml solution; 24 jig) on ventilation-perfusion (VA/Q) relationships, hemodynamics, and resistance of the respiratory system was studied in 14 healthy, nonatopic, and nonsmoking individuals (23±1 ISEMI yr) before and at 2, 4, 6, 8, 15, and 45 min after inhalation, and compared to that of inhaled lyso-PAF in 10 other healthy individuals (24±2 yr). PAF induced, compared to lyso-PAF, immediate leukopenia (P < 0.001) followed by a rebound leukocytosis (P < 0.002), increased minute ventilation (P < 0.05) and resistance of the respiratory system (P < 0.01), and decreased systemic arterial pressure (P < 0.05). Similarly, compared to lyso-PAF, PaO2 showed a trend to fall (by 12.2±4.3 mmHg, mean±SEM maximum change from baseline), and arterial-alveolar O2 gradient increased (by 16.7±4.3 mmHg) (P < 0.02) after PAF, because of VA/Q mismatch: the dispersion of pulmonary blood flow and that of ventilation increased by 0.45±0.1 (P < 0.01) and 0.29±0.1 (P < 0.04), respectively. We conclude that in normal subjects, inhaled PAF results in considerable immediate VA/Q inequality and gas exchange impairment. These results reinforce the notion that PAF may play a major role as a mediator of inflammation in the human lung. (J. Clin. Invest. 1994. 93:188-194.)
Introduction
Platelet-activating factor( PAF) ' is a potent phospholipid mediator of inflammation with a wide spectrum of activity, includ-ing chemotaxis and activation of neutrophils and eosinophils ( 1, 2) , and induction ofboth airway and pulmonary microvascular leakage (3) (4) (5) . When infused into conscious sheep, PAF increases pulmonary vascular resistance, alveolar-arterial 02 gradient (AaPO2), and lymph-to-plasma protein concentration ratio (6, 7) . In humans, inhaled PAF induces bronchoconstriction and an increase in bronchial responsiveness to methacholine associated with a transient neutropenia and with increased number of neutrophils in bronchoalveolar lavage fluid (8, 9) . However, little is known about the potential effects of inhaled PAF or of other inflammatory mediators on pulmonary gas exchange. By contrast, methacholine, a potent bronchoconstrictor agent, induces considerable bronchoconstriction in patients with mild asthma, but only mild to moderate ventilationperfusion (VA/Q) deterioration related to maldistribution of ventilation (10).
Because of these effects of PAF on the pulmonary vasculature and airways ( 11), we postulated that PAF could disturb gas exchange in normal humans, perhaps mimicking some of the abnormalities naturally observed in patients with bronchial asthma or adult respiratory distress syndrome (ARDS). In asthma, the mechanism of abnormal pulmonary gas exchange is VA/Q mismatch without shunt, whereas intrapulmonary shunting predominates in ARDS ( 12) .
To test the hypothesis that PAF could induce pulmonary gas exchange abnormalities, we studied the effects of inhaled PAF on pulmonary gas exchange and hemodynamics and compared to those of inhaled lyso-PAF, the biologically inactive PAF precursor and metabolite, in a group ofhealthy young volunteers.
Methods
Individuals. 24 healthy individuals (21 males and 3 females, ages 18-36 yr) were recruited from the community for the study, which was approved by our center's Research Committee on Human Investigations. All subjects gave written informed consent after the purpose, risks, and potential of the study were explained and understood. Anthropometric, white blood cell, and baseline functional data appear in Table I . All were nonsmokers and nonatopic as judged by one or more wheal-and-flare responses to skin prick tests with common allergen extracts. All subjects were free of respiratory infection for 2 6 wk preceding the study. They demonstrated normal spirometry (values > 80% predicted) and a negative abbreviated methacholine bronchial challenge.
Procedures. Blood samples were collected anaerobically through catheters inserted into the radial and pulmonary arteries. Arterial and mixed venous 02 pressure, CO2 pressure, and pH were analyzed in duplicate using standard electrodes (IL 1302; Instrumentation Laboralet-activating factor; Pa02, partial 02 pressure in arterial blood; PAP, pulmonary arterial pressure; QT, cardiac output; Rrs, respiratory system resistance; RSS, remaining sum of squares; VE, minute ventilation; V02, 02 uptake.
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Rodriguez-Roisin et al. Ru- dolph Instruments, Kansas City, MO) connected to a heated metal mixing chamber was used to collect the mixed expired gas. Oxygen uptake (0Vo2) and CO2 production were calculated from mixed expired 02 and CO2 concentrations measured by mass spectrometry (multigas monitor MS2; BOC-Medishield, London, United Kingdom). Minute ventilation (VE) and respiratory rate (f) were measured using a calibrated Wright spirometer (Respirometer MK8; BOC-Medical, Essex, United Kingdom). The alveolar-arterial 02 gradient (AaPO2) was calculated according to the alveolar gas equation using the measured respiratory exchange ratio. Total respiratory system resistance (Rrs) was measured by forced oscillation applied at the mouth, its analysis being restricted to frequencies between 6 and 10 Hz. Details of the measurement of Rrs in our laboratory are reported in reference 10.
A three-lead electrocardiogram, heart rate (HR), and systemic (Ps) as well as pulmonary arterial (PAP) pressures (using a Swan-Ganz catheter) were continuously recorded throughout the whole study (HP 7830A monitor and HP 7754B recorder; Hewlett-Packard, Waltham, MA). Cardiac output (QT) was calculated according to the Fick principle using the measured Vo2 and the calculated 02 contents of arterial and mixed venous blood. VA/Q distributions were estimated by the multiple inert gas elimination technique (MIGET) (14) , the inert gases being dissolved in normal saline and infused through a peripheral venous cannula. Specific features of this technique in our laboratory have been reported earlier (15, 16) . Ventilation-perfusion distributions were estimated from inert gas data using a least square algorithm with enforced smoothing (17 , baseline measurements were performed. 14 subjects were then challenged with PAF(C16) ( 1-0-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine, fully saturated; Novabiochem AG, Laufelfingen, Switzerland). PAF was kept as stock solution of 10 mg/ml in ethanol at -80'C. Solutions of 2 mg/ml in 0.35% bovine serum albumin were freshly prepared on each study day. Details of the PAF challenge performed in our laboratory have been reported elsewhere ( 18, 19) . PAF was delivered from a nebulizer attached to a dosimeter (Morgan Nebichek, PK Morgan, Chatham, Kent, United Kingdom), driven by compressed air at a pressure of 22 lb/in2 (152 kPa). The output of the nebulizer was 6 ti/breath. We administered two breaths of PAF (24 ,g), subjects inhaling from functional residual capacity to total lung capacity over a period of 5 s followed by a 10-s breathhold for each. Because the time course of gas exchange response to PAF was unknown, we took single measurements 2 min apart during the first 6 min after challenge (at 2, 4, and 6 min ), and then duplicate measurements at 8, 15, and 45 min. In 8 out of the 14 subjects, all sets of measurements consisted of the following steps in sequence: (a) inert gas sampling and recording of VE and f, (b) respiratory gas sampling, (c) systemic and pulmonary hemodynamic recordings (available at all time points in two ofthe eight individuals only), and (d) sampling for circulating blood cells. In the other six individuals, to better evaluate pulmonary artery pressures, identical sets of measurements without inert gas sampling were carried out. Likewise, in the latter six subjects, measurements of Rrs only were performed 1 wk later following identical time course, as the circuit for sampling expired respiratory and inert gases is not suitable for Rrs measurements.
Identical procedures and study design were followed with lyso-PAF (C16) (1-0-hexadecyl-sn-glycero-3-phosphocholine, fully saturated; Novabiochem AG) challenge (two breaths, 24 gg) in 10 other individuals. All these subjects had a complete sets of measurements as after PAF, including measurements of pulmonary artery pressures; in addition, seven only had measurements of Rrs 1 wk later using identical protocol. Except for total white cell counts, no differences were observed in any of the parameters at baseline between the participants who received PAF or lyso-PAF (Tables I-III) .
Maintenance ofsteady-state conditions after the PAF and lyso-PAF challenges was demonstrated by stability (±5%) ofhemodynamic (FHR and Ps) and spirometric (fand tidal volume) variables, and by the close agreement between duplicate measurements ofmixed expired and arterial respiratory gases (within ±5%). These conditions were reached in all but one participant in whom respiratory gases only were measured after PAF. The reliability of the inert gas data is indicated by the remaining sum ofsquares ( RSS) between the measured data and the least squares fit (by the smoothing algorithm [ 17 ] ). We found that the distribution of RSS was within expected levels for a set of six randomly distributed error terms with unit variance at all time points. The mean RSS at each time point was 6.5±0.9 (baseline), 6 .1±2.0 (2 min), 6.3±1.4 (4 min), 3.9±0.7 (6 min), 4.7±0.7 (8 min), 3.8±0.5 (15 min), and 5.6+1.0 (45 min). 94% of RSS were < 15.0, 86% were c 10.0, and 59% < 5.0, and the mean RSS was 5.3±0.3 (150 sets of data obtained). The chi square distribution predicts 97% to be < 15.0, 90%tobe< 10.0, and 55% tobe<5.0 (20) .
Safety precautions. Individuals were instructed that the study could be immediately terminated should unusual symptoms other than flushing and coughing develop, but this was never required. Three physicians were present at all times, with one devoted exclusively to the observation of subjects.
Statistical analysis. Data are reported as mean±SEM. Because the time course of changes after PAF clearly showed an initial response, some plateauing and then return toward baseline conditions, a conventional analysis of variance to determine significance of PAF effects was considered inappropriate. Accordingly, the maximum change from baseline for each outcome variable was considered a suitable summary measure of its individual response profile (21 ) . This considers the individual as the basic unit and uses the responses for each subject to construct a single number that summarizes some aspect ofthat individual's response curve. We chose the maximum change from baseline, which P refers to differences between the maximum changes from baseline after PAF and Lyso-PAF challenges, using Mann-Whitney's test.
may be interpreted as a measure ofthe maximum effect of PAF. Since Except at 4 min after PAF, no overall significant differences distributions of these summary measures clearly showed skewness, were observed between arterial and mixed venous white cell these maximum changes from baseline after PAF and lyso-PAF chalcounts; at that time point, however, both arterial leukopenia lenges were treated as raw data and compared using common nonpara-(3.0±0.4 x 109/liter) (P < 0.007) and neutropenia (1.5±0.4 metric methods (Mann-Whitney's test). Spearman's correlations were X 109/liter) (P < 0.004) were more pronounced.
used to assess the relationships between variables. Wilcoxon's test was Respiratory and inert gas responses (Table III Similarly, Pvo2 decreased initially by 3.9±0.6 mmHg (P X 109/liter)(P < 0.001) within 4 min after PAF inhalation = 0.05). Fig. 1 illustrates the individual time courses of AaPO2, followed by a rebound leukocytosis at 8 min (8.6±0.5 X 109/ in which it is shown that six participants were highly responliter, which persisted at 15 min (10.0±0.8 X 109/liter) and at sive, two were mildly responsive, and five failed to respond to 45 min (9.6±0.6 X 109/liter) (P < 0.002), as noted previously PAF, and Fig. 2 depicts the mean±SEM maximum changes (18) . The fall oftotal white cell count accounted for an early (4 from baseline of AaPO2, after PAF and lyso-PAF challenges. min) reduction (from 4.0±0.3 to 2.0±0.3 x 109/liter) (P There were no significant differences in the baseline data for <0.001) in circulating mixed venous blood neutrophils and a those six subjects who were high responders. By contrast, rebound neutrophilia at 8, 15, and 45 min (to 6.5±0.4, Pa o2,pH, and Vo2 remained essentially stable without signifi-7.9±0.8, and 7.8±0.6 X 109/liter, respectively) (P < 0.002).
cant differences between PAF and lyso-PAF challenges. Baseline VA/Q ratio distributions were narrow and unimodal in all subjects, in agreement with previous inert gas studies in healthy individuals (22-24). After PAF the distribution of pulmonary blood flow and that of alveolar ventilation broad- (Table III) . In Fig. 2 are shown the mean±SEM maximum changes from baseline ofthe latter three variables after PAF and lyso-PAF challenges.
There were no differences in HR (PAF, 71±2 vs lyso-PAF, 75±2 min'), QT 
Discussion
Principal findings. The most novel finding of our study was that after inhaled PAF, healthy individuals with a negative methacholine challenge developed transient, sometimes striking, pulmonary gas exchange abnormalities, together with mild increases in total ventilation and the resistance of the respiratory system and a mild reduction in systemic arterial pressure. principal component of hypoxemia ( 12 ) . Yet, the increase in Rrs was small (of the order of 35%), at least compared to that induced in patients with mild asthma after a dose-response curve bronchial challenge with methacholine (of the order of 88%) ( 10 ). By contrast, lyso-PAF, a substance chemically similar to PAF, albeit biologically inactive, had essentially no effect on any of the variables studied, including pulmonary gas exchange, thereby suggesting that the effects seen after PAF were not related to a nonspecific effect of inhaling a phospholipid. Overall, these results confirm our hypothesis that inhaled PAF is also capable of causing deterioration of VA/Q relationships in healthy individuals. (27) . However, they did not use MIGET to characterize VA/Q changes. PAF has been previously shown to be not only a potent systemic hypotensive agent (28) , but also a pulmonary vasoconstrictor (29) or vasodilator (30) , depending on the dosage and the mode of administration, the animal species studied, and the tone of the underlying vasculature. In our study, inhalation of PAF induced a slight reduction in systemic arte- Interpretation ofgas exchange abnormalities. It is of interest to discuss not only the magnitude but also the similarity of PAF-induced VA/Q changes to those of natural asthma. The deterioration of VA/Q relationships resulted from an increase in the dispersion ofpulmonary blood flow rather than of ventilation, because of the development of low VA/Q regions. This is qualitatively similar to what is seen in patients with bronchial asthma, of moderate (25), severe chronic (31), or the most severe life-threatening acute clinical forms (32, 33) . That the dispersion for blood flow is more abnormal than that for ventilation is commensurate with the underlying pathophysiology of gas exchange abnormalities in patients with asthma, in whom widespread airway narrowing leads to the presence of areas that remain perfused but are poorly ventilated; i.e., areas Oflow VA/Q ratios. It should be noted that the VA/Q abnormalities and reduced Pao2 occurred in the face of any increase of total ventilation, which would be expected to improve both Pao2 and VA/Q relationships, other factors equal (34) . The fall in Pao2 caused by the deterioration of VA/Q relationships after PAF was, therefore, partly offset by the simultaneous effect of increased ventilation.
Another point of interest was the magnitude of change. In absolute terms, and examining mean data, the degree of VA/Q inequalities caused by PAF was mild to moderate. However, given that these were healthy individuals with a nonuniform response to PAF, the changes in some individuals were relatively severe (Fig. 1 ). By comparison, in studies designed to assess the effects ofgas exchange ofboth exercise and simulated high altitude in young healthy men (22, 23), the development Of VA/Q mismatch was much smaller than that seen in the present investigation. Likewise, the administration of the potent vasodilator nifedipine during hypoxia, at rest, in normal volunteers showed a very small increase in the VA/Q dispersion (24) .
Mechanism of action. The mechanism by which PAF induced VA/Q mismatching in our subjects may be related to at least two factors: bronchoconstriction and airway microvascular leakage ( 11) . However, the possibility that the small increases in Rrs shown after PAF in the present study can also reflect changes in the viscoelastic resistance of the lung parenchyma (potentially induced by mild pulmonary edema) rather than to reduction in airway caliber, cannot be ruled out. In addition to overall airways resistance, it is considered that Rrs includes also tissue resistances of the lung and chest wall ( 10). Conceivably, both bronchoconstriction and airway leakage may contribute synergistically to widespread airway narrowing, hence leading to the development of areas of low VA/Q ratios.
However, we suggest that the VA/Q inequalities seen after PAF are more related to altered airway vascular permeability rather than to bronchoconstriction and are consistent with a large body of evidence based upon three complementary findings. First, we have previously shown that inhalation ofPAF in anesthesized guinea pigs induced a large degree ofairway microvascular leakage, but small increases in lung resistance, compared with inhaled histamine and 5-hydroxytryptamine, which have direct contractile effect on airway smooth muscle (35) .
Since airway microvascular leakage correlated significantly with changes in lung resistance, it was suggested that airway edema could be a marked component of airway narrowing induced by PAF. Airway microvascular permeability may occur by either a direct local effect of PAF on the airways (36) or, indirectly, via the activation of neutrophils (3) . Although PAF may induce airway narrowing by causing airway edema in addition to airway smooth muscle contraction ( 18) , PAF has been reported to have either no effect (37) or a modest but variable effect on the contraction of human isolated airways (38) .
A second argument comes also from another study of our group on the effects ofmethacholine challenge on gas exchange in mild asthma (10). In that study, although methacholine (which has a primary effect on airway smooth muscle) caused, in a subgroup ofseven patients with a forced expiratory volume in the first second (FEVy) > 90% predicted and mild VA/Q inequality (mean log SD Q, 0.67) at baseline, a 30% fall in FEVI and a marked increase in the resistance ofthe respiratory system (of the order of 103%) it induced much less VA/Q mismatch (mean increase in log SD Q, 42%) than in the present study. This suggests that even considerable bronchoconstriction per se does not cause necessarily much VA/Q inequality, at least acutely.
Finally, a third line of evidence comes from the study by Rubin et al. (39) , which documented that inhaled PAF, at similar doses used in the present study, induced very small changes in FEV1 (of the order of 5%) in comparison to relatively larger changes in more sensitive tests of airflow obstruction in healthy subjects; similarly, asthmatic patients showed a 10% decrease in FEV, at the same PAF concentration. We now demonstrate similar Rrs changes in our study that indicate that PAF is not potent in inducing airway narrowing. Our data are further reinforced by a recent observation of our group that, using a similar design in another series ofhealthy subjects (40), inhalation of PAF caused similar changes in Rrs and in gas exchange. However, each of these arguments is indirect and, therefore, the mechanism by which PAF induces VA/Q abnormalities in humans requires more direct investigation.
Despite the lack of a significant correlation between preand post-PAF challenge changes in leucocytes and gas exchange, it is clear that there was a temporal association between the two parameters. The question arises as to whether white blood cell changes may be related directly to the mechanism of PAF-induced gas exchange abnormalities. Reversible pulmonary neutrophil sequestration within the lung after inhaled PAF has been recently shown in healthy individuals (41) . In our study, we observed more leukopenia and neutropenia in arterial blood than in the mixed venous blood after PAF, possibly reflecting transient lung sequestration of neutrophils. However, it is of interest to outline that the sequestration of leucocytes in the pulmonary vasculature during hemodialysis, a condition also associated with transient hypoxemia, does not aggravate VA/Q mismatching, or induce 02 diffusion disequilibrium in humans (42) 
